A supportive care in cancer unit reduces costs and hospitalizations for transfusions in a comprehensive cancer center

Carla Ida Ripamonti, Pietro Molani, Cinzia Desti, Giacomo Boscagli, Fernando Ravagnani, Flavio Arienti, Clementina Di Cristo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Among patients with solid or hematologic malignancies undergoing oncologic therapies, blood product transfusions (BPT) are a relevant reason for planned/unplanned hospitalizations, as well as a possible cause of delay in administration of the oncologic therapies. Furthermore, they create additional costs for the healthcare system (HCS). The aim of this study was to compare the costs of performing BPT (erythrocytes and platelets) in medical units/wards to the costs derived from the administration of BPT in a dedicated outpatient supportive care in cancer unit (SCCU). Methods: Costs were analyzed from June 3, 2009 (when the SCCU started), until December 2013. Four inpatient oncologic units (bone marrow transplantation, radiotherapy, medical oncology I and II) were compared to the SCCU. Data regarding the transfusions performed by the SCCU of the patients who were previously hospitalized for transfusions were extracted, checked, and analyzed through a cross-check on the tax codes. Therefore, patients were considered suitable for the analysis if they had received BPT in the SCCU after a previous hospitalization for transfusion in one of the 4 units/wards. The average daily cost deriving from blood product units and from the hospitalization in each ward (irrespective of pharmaceutical expenses) was compared with the average daily cost deriving from blood product units and from the management of patients in the SCCU. Results: We analyzed 227 patients (112 female) with a mean age of 60 years (range 20-90) with hematologic malignancies in 79% of cases. The number of transfusions performed by the SCCU has grown constantly and consistently over the years, reaching 1,402 transfusions in 2013, thus exceeding the other considered units. The total savings for the HCS was €282.204.71, €151.182.85 in 2013 only. We saved €124.319,26 for each patient transfused at the SCCU. Conclusions: A dedicated outpatient SCCU, aimed at monitoring and treating cancer therapy-related toxicities and comorbidities and in which it is also possible to perform BPT promptly and effectively, reduces the number of hospitalizations and provides an economical benefit for HCS.

Original languageEnglish
Pages (from-to)449-456
Number of pages8
JournalTumori
Volume103
Issue number5
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Hospital Oncology Service
Hospitalization
Blood Transfusion
Costs and Cost Analysis
Neoplasms
Hematologic Neoplasms
Ambulatory Care
Delivery of Health Care
Medical Oncology
Second Primary Neoplasms
Taxes
Bone Marrow Transplantation
Comorbidity
Inpatients
Radiotherapy
Blood Platelets
Erythrocytes

Keywords

  • Blood component transfusion
  • Costs
  • Inpatient units
  • Supportive care unit

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A supportive care in cancer unit reduces costs and hospitalizations for transfusions in a comprehensive cancer center. / Ripamonti, Carla Ida; Molani, Pietro; Desti, Cinzia; Boscagli, Giacomo; Ravagnani, Fernando; Arienti, Flavio; Di Cristo, Clementina.

In: Tumori, Vol. 103, No. 5, 01.09.2017, p. 449-456.

Research output: Contribution to journalArticle

Ripamonti, Carla Ida ; Molani, Pietro ; Desti, Cinzia ; Boscagli, Giacomo ; Ravagnani, Fernando ; Arienti, Flavio ; Di Cristo, Clementina. / A supportive care in cancer unit reduces costs and hospitalizations for transfusions in a comprehensive cancer center. In: Tumori. 2017 ; Vol. 103, No. 5. pp. 449-456.
@article{02cf8171058748e6917c5cf60638d678,
title = "A supportive care in cancer unit reduces costs and hospitalizations for transfusions in a comprehensive cancer center",
abstract = "Purpose: Among patients with solid or hematologic malignancies undergoing oncologic therapies, blood product transfusions (BPT) are a relevant reason for planned/unplanned hospitalizations, as well as a possible cause of delay in administration of the oncologic therapies. Furthermore, they create additional costs for the healthcare system (HCS). The aim of this study was to compare the costs of performing BPT (erythrocytes and platelets) in medical units/wards to the costs derived from the administration of BPT in a dedicated outpatient supportive care in cancer unit (SCCU). Methods: Costs were analyzed from June 3, 2009 (when the SCCU started), until December 2013. Four inpatient oncologic units (bone marrow transplantation, radiotherapy, medical oncology I and II) were compared to the SCCU. Data regarding the transfusions performed by the SCCU of the patients who were previously hospitalized for transfusions were extracted, checked, and analyzed through a cross-check on the tax codes. Therefore, patients were considered suitable for the analysis if they had received BPT in the SCCU after a previous hospitalization for transfusion in one of the 4 units/wards. The average daily cost deriving from blood product units and from the hospitalization in each ward (irrespective of pharmaceutical expenses) was compared with the average daily cost deriving from blood product units and from the management of patients in the SCCU. Results: We analyzed 227 patients (112 female) with a mean age of 60 years (range 20-90) with hematologic malignancies in 79{\%} of cases. The number of transfusions performed by the SCCU has grown constantly and consistently over the years, reaching 1,402 transfusions in 2013, thus exceeding the other considered units. The total savings for the HCS was €282.204.71, €151.182.85 in 2013 only. We saved €124.319,26 for each patient transfused at the SCCU. Conclusions: A dedicated outpatient SCCU, aimed at monitoring and treating cancer therapy-related toxicities and comorbidities and in which it is also possible to perform BPT promptly and effectively, reduces the number of hospitalizations and provides an economical benefit for HCS.",
keywords = "Blood component transfusion, Costs, Inpatient units, Supportive care unit",
author = "Ripamonti, {Carla Ida} and Pietro Molani and Cinzia Desti and Giacomo Boscagli and Fernando Ravagnani and Flavio Arienti and {Di Cristo}, Clementina",
year = "2017",
month = "9",
day = "1",
doi = "10.5301/tj.5000627",
language = "English",
volume = "103",
pages = "449--456",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - A supportive care in cancer unit reduces costs and hospitalizations for transfusions in a comprehensive cancer center

AU - Ripamonti, Carla Ida

AU - Molani, Pietro

AU - Desti, Cinzia

AU - Boscagli, Giacomo

AU - Ravagnani, Fernando

AU - Arienti, Flavio

AU - Di Cristo, Clementina

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose: Among patients with solid or hematologic malignancies undergoing oncologic therapies, blood product transfusions (BPT) are a relevant reason for planned/unplanned hospitalizations, as well as a possible cause of delay in administration of the oncologic therapies. Furthermore, they create additional costs for the healthcare system (HCS). The aim of this study was to compare the costs of performing BPT (erythrocytes and platelets) in medical units/wards to the costs derived from the administration of BPT in a dedicated outpatient supportive care in cancer unit (SCCU). Methods: Costs were analyzed from June 3, 2009 (when the SCCU started), until December 2013. Four inpatient oncologic units (bone marrow transplantation, radiotherapy, medical oncology I and II) were compared to the SCCU. Data regarding the transfusions performed by the SCCU of the patients who were previously hospitalized for transfusions were extracted, checked, and analyzed through a cross-check on the tax codes. Therefore, patients were considered suitable for the analysis if they had received BPT in the SCCU after a previous hospitalization for transfusion in one of the 4 units/wards. The average daily cost deriving from blood product units and from the hospitalization in each ward (irrespective of pharmaceutical expenses) was compared with the average daily cost deriving from blood product units and from the management of patients in the SCCU. Results: We analyzed 227 patients (112 female) with a mean age of 60 years (range 20-90) with hematologic malignancies in 79% of cases. The number of transfusions performed by the SCCU has grown constantly and consistently over the years, reaching 1,402 transfusions in 2013, thus exceeding the other considered units. The total savings for the HCS was €282.204.71, €151.182.85 in 2013 only. We saved €124.319,26 for each patient transfused at the SCCU. Conclusions: A dedicated outpatient SCCU, aimed at monitoring and treating cancer therapy-related toxicities and comorbidities and in which it is also possible to perform BPT promptly and effectively, reduces the number of hospitalizations and provides an economical benefit for HCS.

AB - Purpose: Among patients with solid or hematologic malignancies undergoing oncologic therapies, blood product transfusions (BPT) are a relevant reason for planned/unplanned hospitalizations, as well as a possible cause of delay in administration of the oncologic therapies. Furthermore, they create additional costs for the healthcare system (HCS). The aim of this study was to compare the costs of performing BPT (erythrocytes and platelets) in medical units/wards to the costs derived from the administration of BPT in a dedicated outpatient supportive care in cancer unit (SCCU). Methods: Costs were analyzed from June 3, 2009 (when the SCCU started), until December 2013. Four inpatient oncologic units (bone marrow transplantation, radiotherapy, medical oncology I and II) were compared to the SCCU. Data regarding the transfusions performed by the SCCU of the patients who were previously hospitalized for transfusions were extracted, checked, and analyzed through a cross-check on the tax codes. Therefore, patients were considered suitable for the analysis if they had received BPT in the SCCU after a previous hospitalization for transfusion in one of the 4 units/wards. The average daily cost deriving from blood product units and from the hospitalization in each ward (irrespective of pharmaceutical expenses) was compared with the average daily cost deriving from blood product units and from the management of patients in the SCCU. Results: We analyzed 227 patients (112 female) with a mean age of 60 years (range 20-90) with hematologic malignancies in 79% of cases. The number of transfusions performed by the SCCU has grown constantly and consistently over the years, reaching 1,402 transfusions in 2013, thus exceeding the other considered units. The total savings for the HCS was €282.204.71, €151.182.85 in 2013 only. We saved €124.319,26 for each patient transfused at the SCCU. Conclusions: A dedicated outpatient SCCU, aimed at monitoring and treating cancer therapy-related toxicities and comorbidities and in which it is also possible to perform BPT promptly and effectively, reduces the number of hospitalizations and provides an economical benefit for HCS.

KW - Blood component transfusion

KW - Costs

KW - Inpatient units

KW - Supportive care unit

UR - http://www.scopus.com/inward/record.url?scp=85031116754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031116754&partnerID=8YFLogxK

U2 - 10.5301/tj.5000627

DO - 10.5301/tj.5000627

M3 - Article

C2 - 28478645

AN - SCOPUS:85031116754

VL - 103

SP - 449

EP - 456

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -